The Food and Drug Administration has recently announced that it approved Merck & Co’s Ebola vaccine, Ervebo.
Ervebo which is administered as a single-does injection helps in preventing the virus from developing in patients aged 18 years and above.
The vaccine was first tested by the WHO and the Democratic Republic of the Congo to reduce the number of Ebola outbreaks in some of the West African states.
Ebola Virus has caused over 2,000 deaths in Congo alone in the first half of 2019, making it the second-largest outbreak to date.
It causes hemorrhagic fever and easily transfers from people to people through contact with body fluids.
Merck & Co received approval from the European Commission to market the Ebola Vaccine back in November and is pleased that the FDA has approved the vaccine, as Merck & Co express its hope that the vaccine will change the game against the fight with Ebola Virus.